QCA First — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria.
BiotechHealthtechMedical DevicesAnnapolis, US
Gary Pekoe(Co-founder & Chief Scientific Officer)Neal Koller(Co-founder & CEO, Chairman of the Board)Steven Pentelnik(Co-founder & President)Jazmyne Mink(Co-founder & Regulatory Affairs Director)
Board seatTony Shipley· per SEC Form D · $5.2M raise · filed Apr 2024
Co-investorsAngel Physicians Fund
Cincinnati, US
Steven Levin(Executive Officer, Director)Adam Malofsky(Executive Officer, Director)Malofsky Adam(Executive Officer, Director)
BoardJohn H. Abeles(Director)
Board seatJohn Habbert· per SEC Form D · $5.5M raise · filed Jan 2026
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.